EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

OnabotulinumtoxinA Is an Effective Treatment for Reducing the Interictal Burden in Patients with Chronic Migraine: A Prospective Observational Study

Alejandro Sánchez-Huertas, Oscar Camejo-Mas, Sebastian Garcia-Roldan, Rocio Alonso-Castillo, Lara Pulido-Fraiz, Andrea Higuera Ruiz de la Hermosa, Leonardo Portocarrero-Sánchez, Javier Díaz-de-Terán iD

Toxins · 16.09.2025 · 17 (9) · 463

DOI: 10.3390/toxins17090463 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Toxins, online erschienen am 16.09.2025. Verfasst von Alejandro Sánchez-Huertas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Hospital Universitario La Paz, 28046 Madrid, Spain. Hauptthemen laut MEDLINE: Migraine Disorders, Botulinum Toxins, Type A. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: La Paz Institute for Health Research (IdiPAZ).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interictal burden (IB), defined as the symptoms and impairments that occur between migraine attacks, including cognitive dysfunction, photophobia, and fatigue, is recognized as a significant determinant of quality of life in patients. A prospective observational study was conducted. Patients diagnosed with chronic migraine (CM) and under treatment with OnabotulinumtoxinA (OnabotA) according to the PREEMPT protocol (every 12 weeks) were assessed at baseline and at 3, 6, 9, and 12 months. The primary endpoint was to evaluate the change in the IB measured with the Migraine Interictal Burden Scale (MIBS-4) and in the monthly migraine days (MMD). The secondary endpoint was acute medication use. This single-center study included 150 patients (91.3% female; median age 44 years). MIBS-4 scores were decreased by 29.1% at 3 months (8.47 to 5.97) and by 41.6% at 12 months (to 4.86; p < 0.001). IB-free status was achieved by 16 patients (10.7%). The most disabling baseline symptoms were photophobia (37%), fatigue (20%), and allodynia (18%), which reduced by 52%, 43%, and 39% at 12 months, respectively. MMD were reduced from 18.6 to 8.3 days at 12 months and triptan and analgesic intake decreased by 58.7% and 55.4%. OnabotA significantly reduced both IB and migraine frequency over 12 months, underscoring its relevance in CM management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersBotulinum Toxins, Type AHumansFemaleMaleAdultMiddle AgedProspective StudiesChronic DiseaseTreatment OutcomeQuality of Life

Stichwörter der Autor:innen

OnabotulinumtoxinAchronic migraineinterictal burdeninterictal symptomsmigrainequality of life

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin A

Autor:innen und Institutionen

  • Neurology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
  • Hospital La Paz Institute for Health Research (IdiPAZ), Hospital Universitario La Paz, University Autónoma de Madrid, 28046 Madrid, Spain.

ORCID-Profile: Javier Díaz-de-Terán

Förderung

  • La Paz Institute for Health Research (IdiPAZ)

Zitieren

APA

Sánchez-Huertas, A., Camejo-Mas, O., Garcia-Roldan, S., Alonso-Castillo, R., Pulido-Fraiz, L., Higuera Ruiz de la Hermosa, A., Portocarrero-Sánchez, L., & Díaz-de-Terán, J. (2025). OnabotulinumtoxinA Is an Effective Treatment for Reducing the Interictal Burden in Patients with Chronic Migraine: A Prospective Observational Study. Toxins, 17(9), 463. https://doi.org/10.3390/toxins17090463

Vancouver

Sánchez-Huertas A, Camejo-Mas O, Garcia-Roldan S, Alonso-Castillo R, Pulido-Fraiz L, Higuera Ruiz de la Hermosa A, et al. OnabotulinumtoxinA Is an Effective Treatment for Reducing the Interictal Burden in Patients with Chronic Migraine: A Prospective Observational Study. Toxins. 2025;17(9):463. doi:10.3390/toxins17090463

BibTeX
@article{SnchezHuertas2025,
  author = {Sánchez-Huertas, Alejandro and Camejo-Mas, Oscar and Garcia-Roldan, Sebastian and Alonso-Castillo, Rocio and Pulido-Fraiz, Lara and Higuera Ruiz de la Hermosa, Andrea and Portocarrero-Sánchez, Leonardo and Díaz-de-Terán, Javier},
  title = {OnabotulinumtoxinA Is an Effective Treatment for Reducing the Interictal Burden in Patients with Chronic Migraine: A Prospective Observational Study},
  journal = {Toxins},
  year = {2025},
  volume = {17},
  number = {9},
  pages = {463},
  doi = {10.3390/toxins17090463}
}
Kostenlos starten →